

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 12 September 2019 (the “**Prospectus**”) issued by Shanghai Henlius Biotech, Inc. (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (and its territories, possessions and all areas subject to its jurisdiction) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilising or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it, to conduct any such stabilising action, which, if taken, will be done at the sole and absolute discretion of the Stabilising Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilising activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilising action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilising) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilising action cannot be taken to support the price of the H Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on 17 October 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.





The Offer Price will not be more than HK\$57.80 per Offer Share and it is expected to be not less than HK\$49.60 per Offer Share, unless the Board announces a further increase in the section headed "Structure of the Global Offering in the Prospectus". Applications for the Hong Kong Offer Shares and the Reserved Shares are invited on a non-allocation basis, the maximum Offer Price of HK\$57.80 per Offer Share, brokerage of 1.0%, SFC transaction fee of 0.0027% and Stock Exchange trading fee of 0.005%, subject to confirmation of the Offer Price as finally determined, will not be less than HK\$57.80 per Offer Share.

**Applications for the Hong Kong Offer Shares and Reserved Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for the White Form eIPO, the Orange Form eIPO and the Blue Form eIPO.**

Applicants who would like to be allotted the Hong Kong Offer Shares registered in their own name should either (i) complete and sign the **WHITE Allocation Form**; or (ii) submit an application online through the designated website of the **White Form eIPO Service Provider** at [www.eipo.com.hk](http://www.eipo.com.hk), under the **White Form eIPO** service. Applicants who would like to be allotted the Hong Kong Offer Shares registered in the name of HKSCC Nominee and deposited directly in CCASS through their CCASS Investor Participant's check account or the check account of their designated CCASS Participant should either (i) complete and sign the **YELLOW Allocation Form**; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Qualifying Foreign Institutional Shareholders who would like to be allotted the Reserved Shares under the Preferential Offering should either (i) complete and sign the **ORANGE Allocation Form**; or (ii) submit an application online through the **Orange Form eIPO** service via [www.eipo.com.hk](http://www.eipo.com.hk).

Qualifying Foreign Pharma Shareholders who would like to be allotted the Reserved Shares under the Preferential Offering should either (i) complete and sign the **BLUE Allocation Form**; or (ii) submit an application online through the **Blue Form eIPO** service via [www.eipo.com.hk](http://www.eipo.com.hk).



<b>New Territories</b>	Mei Chi Branch	Shop 209, Level 2, Mei Chi Phase 1, Tseung Kwan O, New Territories
	Ma On Shan Plaza Branch	Shop 2103, Level 2, Ma On Shan Plaza, Sai Sha Road, Ma On Shan, New Territories

**CMB Wing Lung Bank Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	Head Office	45 Des Voeux Road Central
	Kenned Town Branch	28 Cathick Street
<b>Kowloon</b>	Mingkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Canton Road
<b>New Territories</b>	Tuen Wan Branch	251 Sha Tsui Road

2. and of the following office of the below listed Global Coordinators:

**China International Capital Corporation Hong Kong Securities Limited**  
 29th Floor, One International Finance Centre  
 1 Harbour View Street  
 Central  
 Hong Kong

**Merrill Lynch (Asia Pacific) Limited**  
 Level 55, Cheung Kong Centre  
 2 Queen's Road Central  
 Central  
 Hong Kong

**BOCI Asia Limited**  
 26th Floor, Bank of China Tower  
 1 Garden Road  
 Central  
 Hong Kong

**UBS AG Hong Kong Branch**  
 52/F, Two International Finance Centre  
 8 Finance Street  
 Central  
 Hong Kong

**CMB International Capital Limited**

45/F, Cham i n T ɛ

3 Gæ den R ad

Cen ɔ al

H ng K ng

**Fosun Hani Securities Limited**

S ɔ i e 2101-2105 21/F Cham i n T ɛ

3 Gæ den R ad

Cen ɔ al

H ng K ng

3. he De i ɔ C , n ɛ f HKSCC a 1/F, One & T E change S , æ e, 8 C nna ɔ gh Place, Cen ɔ al, H ng K ng.

**Details of where printed Prospectuses may be obtained will be displayed prominently at every designated branch of receiving banks where WHITE Application Forms are distributed.**

Dr ɔ ng n ɔ mal b ɔ ine h , ɔ f m 9:00 a.m. n Th , ɔ da , 12 Se ɛ mbe ɔ 2019 , n il 12:00 n n n T , e da , 17 Se ɛ mbe ɔ 2019, a lea h ɔ ee c ɔ ie f he ɔ in ed P ɔ ec , ɔ ill be a ailable f ɔ in e c i n a e ɔ l ca i n h ɔ ee he **WHITE** and **YELLOW** A lica i n F ɔ m æ e di ɔ ib , e d a e , in he e c i n headed H A l f ɔ H ng K ng Off ɔ Sh æ e and Re ɔ ed Sh æ e , in he P ɔ ec , .

C ɔ ie f he **WHITE** A lica i n F ɔ m ma b e b ained dr ɔ ng n ɔ mal b ɔ ine h , ɔ f m 9:00 a.m. n Th , ɔ da , 12 Se ɛ mbe ɔ 2019 , n il 12:00 n n n T , e da , 17 Se ɛ mbe ɔ 2019 a h e f ll ɔ ng l ca i n :

1. an f he f ll ɔ ng b ɔ anche f he ɔ ecei ing bank f ɔ he H ng K ng P , blic Off ɔ ing:

**Bank of China (Hong Kong) Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	De V e , R ad We B ɔ anch	111-119 De V e , R ad We , H ng K ng
	Chai Wan B ɔ anch	Bl ck B , Wal n E a e , 341-343 Chai Wan R ad , Chai Wan, H ng K ng

<b>Kowloon</b>	Telford Plaza Branch	Shop Units P2-P7, Telford Plaza, Nos. 33 Wai Yi Street, Kowloon Bay, Kowloon
	Olympian City Branch	Shop 133, 1/F, Olympian City 2, 18 Hoi Ting Road, Kowloon
<b>New Territories</b>	Mercer City Branch	Shop 209, Level 2, Mercer City Phase 1, Tuen King Kwan O, New Territories
	Ma On Shan Plaza Branch	Shop 2103, Level 2, Ma On Shan Plaza, Sai Sha Road, Ma On Shan, New Territories

**CMB Wing Lung Bank Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	Head Office	45 Des Voeux Road Central
	Kennedytown Branch	28 Cathick Street
<b>Kowloon</b>	Mongkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
	Tim Sha Tei Branch	4 Cantonment Road
<b>New Territories</b>	Tuen Wan Branch	251 Sha Tei Road

2. In addition, the following offices of the below listed Global Coordinators:

**China International Capital Corporation Hong Kong Securities Limited**  
 29th Floor, One International Finance Centre  
 1 Harbour View Street  
 Central, Hong Kong

**Merrill Lynch (Asia Pacific) Limited**  
 Level 55, Cheung Kong Centre  
 2 Queen's Road Central  
 Central  
 Hong Kong

**BOCI Asia Limited**  
 26th Floor, Bank of China Tower  
 1 Garden Road  
 Central  
 Hong Kong

**UBS AG Hong Kong Branch**

52/F, Tower 1 International Finance Centre  
8 Finance Street  
Central  
Hong Kong

**CMB International Capital Limited**

45/F, Chamber 1 Tower 1  
3 Garden Road  
Central  
Hong Kong

**Fosun Hani Securities Limited**

Suite 2101-2105 21/F Chamber 1 Tower 1  
3 Garden Road  
Central  
Hong Kong

Copies of the **YELLOW** Allocation Form, may be obtained during normal business hours from 9:00 a.m. on Thursday, 12 September 2019, until 12:00 noon on Tuesday, 17 September 2019 from the Depository Company of HKSCC at 1/F, One & Tower Exchange Square, 8 Canal Street, Central, Hong Kong by clicking on the link below.

The completed **WHITE** and **YELLOW** Allocation Form, together with a check, to be sent to a bank's cashier and attached and marked as **BANK OF CHINA (HONG KONG) NOMINEES LIMITED - HENLIUS BIOTECH PUBLIC OFFER** for the applicant, should be deposited in the special collection box provided at any of the designated branches of the receiving bank listed above, at the following time:

**Thursday, 12 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Friday, 13 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Monday, 16 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Tuesday, 17 September 2019 — 9:00 a.m. to 12:00 noon**

An **ORANGE** Allocation Form and a **BLUE** Allocation Form have been distributed to each Qualifying Foreign Institutional Shareholder and Qualifying Foreign Qualifying Pharma Household, as the case may be, on or before Thursday, 12 September 2019. Electronic copies of the Prospectus can be viewed from here [ecieebie.com](http://ecieebie.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk), under the section headed *HKEXnews > Listed Company Information > Latest Information*.

Qualifying Foreign Institutional Shareholders here, replace  
**ORANGE Allocation Form** & Qualifying Foreign Pharma Shareholders here, replace  
**BLUE Allocation Form** held by CMC, & have  
Hong Kong Investor Service Limited at 17M Floor, Hell Centre, 183  
Queen's Road East, Wanchai, Hong Kong & in the line 2862 8555. Printed  
copy of the Prospectus, can be collected from the branch of the designated  
receiving bank at the office of the Joint Global Coordinator as addressed below.

Allocation matters will be available through the **White Form eIPO** & **Orange Form eIPO** & **Blue Form eIPO** & will be available  
at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last day of  
allocation) from 9:00 a.m. on Thursday, 12 September 2019, until 11:30 a.m.  
on Tuesday, 17 September 2019 and the last time for completion of  
allocation will be 12:00 noon on Tuesday, 17 September 2019 & the last time as described in the  
Hong Kong Offer Share and Redeemed Share D. Effect of Bad Weather on the Opening and Closing of the Allocation List in the  
Prospectus.

The completed **BLUE** & **ORANGE Allocation Form**, together with the  
banker's certificate attached and marked as **BANK OF CHINA  
(HONG KONG) NOMINEES LIMITED - HENLIUS BIOTECH  
PREFERENTIAL OFFER** for the applicant, should be deposited in the special  
collection box provided at the branch of the receiving bank listed  
above, at the following time:

**Thursday, 12 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Friday, 13 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Monday, 16 September 2019 — 9:00 a.m. to 5:00 p.m.**  
**Tuesday, 17 September 2019 — 9:00 a.m. to 12:00 noon**

CCASS Investor Participant can in, **electronic application instructions** from  
9:00 a.m. on Thursday, 12 September 2019, until 12:00 noon on Tuesday, 17  
September 2019 (24 hours daily, except on Tuesday, 17 September 2019, the last  
day of allocation). The last time for entering **electronic application  
instructions** will be 12:00 noon on Tuesday, 17 September 2019, the last day of  
allocation (the last time as described in Hong Kong Offer Share and Redeemed Share  
D. Effect of Bad Weather on the Opening and Closing of the Allocation List in the  
Prospectus).

Please refer to the section headed "Structure of the Global Offering" and  
Hong Kong Offer Share and Redeemed Share in the Prospectus for  
detail of

The Company will announce the final Offer Price, the level of indication of interest in the International Offering, the level of allocation in the Hong Kong Public Offering and the Preferential Offering and the basis of allocation for the Hong Kong Offer Shares and the Redeemed Shares on Tuesday, 24 September 2019 (i) in South China Morning Post (in English); (ii) in Hong Kong Economic Times (in Chinese); (iii) on the website [www.henlius.com](http://www.henlius.com); and (iv) on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

The relevant allocation and the Hong Kong identification card/ application/Hong Kong business registration number for each applicant under the Hong Kong Public Offering and the Preferential Offering will be made available at the time and date and in a manner described in the section headed "How to Apply for Hong Kong Offer Shares and Redeemed Shares" in the Prospectus.

The Company will now receive the application documents for each applicant for allocation fee received. Share certificates will not become valid certificates of file at 8:00 a.m. on Wednesday, 25 September 2019 and the Global Offering has become non-discriminatory in all respects and the high frequency of dealing described in the section headed "Underwriting" has not been exercised.

Dealing in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, 25 September 2019. The H Shares will be traded in blocks of 100 H Shares each, under the Company's tick code 2696.

By order of the Board of Directors  
**Shanghai Henlius Biotech Inc.**  
**Qiyu Chen**  
*Chairman*

Shanghai, 12 September 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Scott Shi-Kau Liu as the executive Director, Mr. Qiyu Chen as the chairman and non-executive Director, Mr. Yifang Wu, Mr. Jiemin Fu, Mr. Aimin Hui and Ms. Xiaohui Guan as the non-executive Directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Mr. Ruilin Song as the independent non-executive Directors.*

*Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).*